Statins and risk of diabetes
Pro Research Analysisby 
Searched over 200M research papers
Statins and Increased Risk of Diabetes: Evidence from Clinical Trials and Observational Studies
Multiple large studies and meta-analyses have consistently found that statin therapy is associated with a modestly increased risk of developing type 2 diabetes. Randomized controlled trials and observational studies show that statin use raises the risk of new-onset diabetes by about 9% to 14% compared to non-users, with some studies reporting even higher relative risks in certain populations or with specific statins 1256+4 MORE. This increased risk is seen across different statin types, including atorvastatin, simvastatin, and rosuvastatin, and appears to be a class effect 158.
Statin Intensity and Diabetes Risk
The risk of developing diabetes is higher with high-intensity statin therapy compared to moderate-intensity regimens. High doses of statins such as atorvastatin 80 mg and rosuvastatin 20 mg are linked to a greater excess risk of diabetes than lower doses or less potent statins 379. The risk also appears to be dose-dependent, with higher statin doses leading to greater impairment in glucose metabolism 89.
Mechanisms: How Statins May Increase Diabetes Risk
Research suggests that statins may increase diabetes risk by impairing insulin sensitivity and reducing insulin secretion. Statin therapy can decrease insulin sensitivity by about 24% and insulin secretion by about 12%, contributing to higher blood glucose levels and increased diabetes risk 38910. The underlying mechanisms may involve inhibition of HMG CoA reductase, leading to changes in cholesterol metabolism, weight gain, and direct effects on pancreatic beta cells and adipose tissue 3479+1 MORE. Genetic studies also support a link between statin action and increased diabetes risk 37.
Populations at Higher Risk
The increased risk of diabetes with statin use is most pronounced in individuals who already have risk factors for diabetes, such as those with prediabetes or features of metabolic syndrome 36910. In high-risk populations, statin therapy still raises diabetes risk, and this effect is not explained by confounding factors such as indication for statin use .
Clinical Implications and Risk-Benefit Balance
Despite the increased risk of diabetes, the absolute risk remains low—typically one extra case of diabetes per 100–200 statin users over five years 27. The cardiovascular benefits of statins, especially in people at moderate or high risk for heart disease, far outweigh the small increase in diabetes risk 2347+2 MORE. Patients should be informed about the slight diabetes risk and encouraged to adopt healthy lifestyle changes, which can help offset this risk and further reduce cardiovascular events . Regular monitoring of blood glucose or HbA1c is recommended after starting statin therapy, particularly in those with existing risk factors for diabetes 79.
Conclusion
Statin therapy is associated with a modestly increased risk of developing type 2 diabetes, especially with higher doses and in individuals already at risk. The main mechanisms involve reduced insulin sensitivity and secretion. However, the cardiovascular benefits of statins greatly outweigh the small risk of diabetes, and statins remain a cornerstone of cardiovascular disease prevention. Careful monitoring and lifestyle advice can help manage this risk in clinical practice.
Sources and full results
Most relevant research papers on this topic